Histone deacetylase inhibition suppresses myogenin-dependent atrogene activation in spinal muscular atrophy mice.

Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease caused by mutations in the survival of motor neuron 1 (SMN1) gene and deficient expression of the ubiquitously expressed SMN protein. Pathologically, SMA is characterized by motor neuron loss and severe muscle atrophy. During muscle atrophy, the E3 ligase atrogenes, atrogin-1 and muscle ring finger 1 (MuRF1), mediate muscle protein breakdown through the ubiquitin proteasome system. Atrogene expression can be induced by various upstream regulators. During acute denervation, they are activated by myogenin, which is in turn regulated by histone deacetylases 4 and 5. Here we show that atrogenes are induced in SMA model mice and in SMA patient muscle in association with increased myogenin and histone deacetylase-4 (HDAC4) expression. This activation during both acute denervation and SMA disease progression is suppressed by treatment with a histone deacetylase inhibitor; however, this treatment has no effect when atrogene induction occurs independently of myogenin. These results indicate that myogenin-dependent atrogene induction is amenable to pharmacological intervention with histone deacetylase inhibitors and help to explain the beneficial effects of these agents on SMA and other denervating diseases.

[1]  M. Bowerman,et al.  Glucose metabolism and pancreatic defects in spinal muscular atrophy , 2012, Annals of neurology.

[2]  C. Lorson,et al.  Transgenic inactivation of murine myostatin does not decrease the severity of disease in a model of Spinal Muscular Atrophy , 2012, Neuromuscular Disorders.

[3]  Zhihua Feng,et al.  Severe neuromuscular denervation of clinically relevant muscles in a mouse model of spinal muscular atrophy. , 2012, Human molecular genetics.

[4]  K. Matsumura,et al.  Histone deacetylase inhibitor trichostatin A enhances myogenesis by coordinating muscle regulatory factors and myogenic repressors. , 2011, Biochemical and biophysical research communications.

[5]  S. Bodine,et al.  Muscle sparing in muscle RING finger 1 null mice: response to synthetic glucocorticoids , 2011, The Journal of physiology.

[6]  K. Fischbeck,et al.  Increasing expression and decreasing degradation of SMN ameliorate the spinal muscular atrophy phenotype in mice. , 2011, Human molecular genetics.

[7]  C. Ko,et al.  Treatment with trichostatin A initiated after disease onset delays disease progression and increases survival in a mouse model of amyotrophic lateral sclerosis , 2011, Experimental Neurology.

[8]  Young Il Lee,et al.  Muscles in a mouse model of spinal muscular atrophy show profound defects in neuromuscular development even in the absence of failure in neuromuscular transmission or loss of motor neurons. , 2011, Developmental biology.

[9]  D. Goldman,et al.  Myogenin regulates denervation‐dependent muscle atrophy in mouse soleus muscle , 2011, Journal of cellular biochemistry.

[10]  D. Sterner,et al.  Targeting the Ubiquitin E3 Ligase MuRF1 to Inhibit Muscle Atrophy , 2011, Cell Biochemistry and Biophysics.

[11]  Michael J. O'Donovan,et al.  Early Functional Impairment of Sensory-Motor Connectivity in a Mouse Model of Spinal Muscular Atrophy , 2011, Neuron.

[12]  E. Olson,et al.  Myogenin and Class II HDACs Control Neurogenic Muscle Atrophy by Inducing E3 Ubiquitin Ligases , 2010, Cell.

[13]  S. Lecker,et al.  Atrogin-1 and MuRF1 regulate cardiac MyBP-C levels via different mechanisms. , 2010, Cardiovascular research.

[14]  C. Lorson,et al.  Effect of diet on the survival and phenotype of a mouse model for spinal muscular atrophy. , 2010, Biochemical and biophysical research communications.

[15]  C. Lutz,et al.  Inhibition of myostatin does not ameliorate disease features of severe spinal muscular atrophy mice. , 2009, Human molecular genetics.

[16]  S. Gygi,et al.  During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation , 2009, The Journal of cell biology.

[17]  G. Lanfranchi,et al.  Different atrophy-hypertrophy transcription pathways in muscles affected by severe and mild spinal muscular atrophy , 2009, BMC medicine.

[18]  C. Lorson,et al.  Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy. , 2009, Human molecular genetics.

[19]  Xiang-Jiao Yang,et al.  A histone deacetylase 4/myogenin positive feedback loop coordinates denervation-dependent gene induction and suppression. , 2009, Molecular biology of the cell.

[20]  M. Rich,et al.  Impaired Synaptic Vesicle Release and Immaturity of Neuromuscular Junctions in Spinal Muscular Atrophy Mice , 2009, The Journal of Neuroscience.

[21]  Barrington G. Burnett,et al.  Sustained improvement of spinal muscular atrophy mice treated with trichostatin a plus nutrition , 2008, Annals of neurology.

[22]  L. Landmesser,et al.  Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy. , 2008, Human molecular genetics.

[23]  V. Rybin,et al.  Muscle RING-finger protein-1 (MuRF1) as a connector of muscle energy metabolism and protein synthesis. , 2008, Journal of molecular biology.

[24]  M. Rudnicki,et al.  The molecular regulation of muscle stem cell function. , 2008, Cold Spring Harbor symposia on quantitative biology.

[25]  A. Goldberg,et al.  FoxO3 controls autophagy in skeletal muscle in vivo. , 2007, Cell metabolism.

[26]  S. Rakhilin,et al.  The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. , 2007, Cell metabolism.

[27]  K. Fischbeck,et al.  Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. , 2007, The Journal of clinical investigation.

[28]  D. Goldman,et al.  Activity-dependent gene regulation in skeletal muscle is mediated by a histone deacetylase (HDAC)-Dach2-myogenin signal transduction cascade , 2006, Proceedings of the National Academy of Sciences.

[29]  Christian C Witt,et al.  MURF-1 and MURF-2 target a specific subset of myofibrillar proteins redundantly: towards understanding MURF-dependent muscle ubiquitination. , 2005, Journal of molecular biology.

[30]  U. Monani,et al.  SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. , 2005, Human molecular genetics.

[31]  T. Prior,et al.  Homozygous SMN1 deletions in unaffected family members and modification of the phenotype by SMN2 , 2004, American journal of medical genetics. Part A.

[32]  W. Frontera,et al.  IKKβ/NF-κB Activation Causes Severe Muscle Wasting in Mice , 2004, Cell.

[33]  A. Goldberg,et al.  IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. , 2004, American journal of physiology. Endocrinology and metabolism.

[34]  G. Yancopoulos,et al.  The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. , 2004, Molecular cell.

[35]  Marco Sandri,et al.  Foxo Transcription Factors Induce the Atrophy-Related Ubiquitin Ligase Atrogin-1 and Cause Skeletal Muscle Atrophy , 2004, Cell.

[36]  W. Frontera,et al.  IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. , 2004, Cell.

[37]  D J Glass,et al.  Identification of Ubiquitin Ligases Required for Skeletal Muscle Atrophy , 2001, Science.

[38]  U. Monani,et al.  The survival motor neuron (SMN) protein: effect of exon loss and mutation on protein localization , 2000, Neurogenetics.

[39]  Hung Li,et al.  A mouse model for spinal muscular atrophy , 2000, Nature Genetics.

[40]  J. McPherson,et al.  A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. , 1999, Human molecular genetics.

[41]  C. Lorson,et al.  A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[42]  A. Goldberg,et al.  Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. , 1999, The Journal of nutrition.

[43]  A. Goldberg,et al.  Rates of ubiquitin conjugation increase when muscles atrophy, largely through activation of the N-end rule pathway. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[44]  J. Weissenbach,et al.  Identification and characterization of a spinal muscular atrophy-determining gene , 1995, Cell.

[45]  William H. Klein,et al.  Muscle deficiency and neonatal death in mice with a targeted mutation in the myogenin gene , 1993, Nature.

[46]  P. Chase,et al.  Different mechanisms of increased proteolysis in atrophy induced by denervation or unweighting of rat soleus muscle. , 1990, Metabolism: clinical and experimental.